Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

15.06 +0.31 (+2.14%)
Streaming Delayed Price Updated: 1:09 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atrium Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Avidity Biosciences Zoomed to a 12% Gain This Week ↗
The company's most promising pipeline program can continue unabated. 
Via The Motley Fool
News headline image
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases ↗
Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular... 
Via Benzinga
News headline image
Unveiling 7 Analyst Insights On Avidity Biosciences ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease ↗
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
News headline image
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings) ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 7 Takes On Avidity Biosciences ↗
 
Via Benzinga
News headline image
(RNA) - Analyzing Avidity Biosciences's Short Interest ↗
 
Via Benzinga
News headline image
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
Via MarketBeat
News headline image
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024 ↗
RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics ↗
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
Via Investor's Business Daily
News headline image
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) ↗
These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market. 
Via InvestorPlace
News headline image
Chart Of The Day: Avidity Biosciences - Something's Up? ↗
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. 
Via Talk Markets
News headline image
A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts ↗
 
Via Benzinga
News headline image
3 Russell 2000 Growth Stocks That Could Be Worth the Risk ↗
These three small-cap stocks could deliver hefty returns if the central bank cuts rates. 
Via The Motley Fool
Topics Economy
News headline image
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing ↗
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
News headline image
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows ↗
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio? ↗
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. 
Via Benzinga
News headline image
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday ↗
 
Via Benzinga
News headline image
Crude Oil Moves Higher; Vera Bradley Shares Slide ↗
 
Via Benzinga
News headline image
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher ↗
 
Via Benzinga
News headline image
Why Avidity Biosciences Shares Are Trading Higher Wednesday ↗
The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran. 
Via Benzinga
News headline image
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point ↗
The company is working on a treatment for a rare form of muscular dystrophy. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
2 Potentially High-Reward Growth Stocks to Buy Right Now ↗
These two biotechnology stocks could be gearing up for a run. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.